Tki258

NSG (NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/SzJ) mice (obtained from the Jackson Laboratories), were maintained as a breeding colony. All experiments were conducted under Augusta University IACUC approved protocols. Female, 6–8 week old mice were used in all xenograft experiments. Mice were engrafted with 1–2 × 10⁶ cells via tail vein injection. All mice were treated with either drug, or vehicle control (PEG300:acetic buffer = 1:1), orally using a gavage needle once per day. All treatments were performed 5 days per week for 4 weeks.
Ponatinib was provided by Ariad Pharmaceuticals Inc. (Cambridge, MA). PD173074 was purchased from Cayman Chemical, AZD4547 and BGJ398 from ChemieTek, JNJ-42756493 from Active Biochem and TKI258 from LC Laboratories. E3810 was provided by EOS pharmaceuticals. All drugs were dissolved in DMSO and stored at −80°C before use. For drug treatments, cells were seeded at 3,000–10,000 cells/well, depending on the cell line, in 96-well plates and incubated overnight. Cells were then treated with either DMSO (control) or different FGFR inhibitors as indicated in the results section at concentrations defined by the experiments. Cell viability was determined using CellTiter-Glo® luminescence cell viability kits (Promega) and a SpectraMax® M5e (Molecular Probes) luminescence plate reader as described previously.^{8 (link)}